Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration. The trial investigated the safety,
Novo Nordisk A/S: Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...
Donald Trump insisted he was serious in his determination to take over Greenland in a fiery telephone call with Denmark’s ...
TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed ...
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK515.00.
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
"Trump might forget about Greenland. But also, he might not. Nobody knows. He operates on whims," @anneapplebaum writes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback